Metastatic colorectal cancer had become a potentially curable disease. Profound improvements in the outcomes of patients with metastatic colorectal cancer over the past years have been attributed to increased use of metastasectomy in selected patients and more effective chemotherapy. It is vital to choose the optimal conventional C/T combination for patients with initially unresectable liver tumors. The addition of Biologics (such as Cetuximab or Bevacizumab) to chemotherapy improves response rates and increases the proportion of metastatic tumor resection.